Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

NCT04579133 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

140

Enrollment

OTHER

Sponsor class

Stopped Not approved

Conditions

Bladder Cancer
Urothelial Carcinoma

Interventions

DRUG: Olaparib
DRUG: Durvalumab

Sponsor

Latin American Cooperative Oncology Group